T he major biological actions of the renin-angiotensin system are mediated by angiotensin (Ang) II, which binds with equal affinity to Ang type 1 (AT 1 ) and type 2 (AT 2 ) receptors. The majority of Ang II actions, however, are mediated by the AT 1 receptor, including vasoconstriction, cellular proliferation, tissue growth, direct renal tubular sodium reabsorption, sympathetic nervous stimulation, and aldosterone secretion, which, in aggregate, lead to a rise in blood pressure. 1 Because the AT 1 receptor is expressed ubiquitously in relatively high levels at renal and cardiovascular sites, an increase in blood pressure represents the net response to increased circulating Ang II.
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By contrast, AT 2 receptors carry a relatively low level of tissue expression in the adult compared with that of AT 1 receptors. 1 AT 2 receptors are expressed in large quantities in fetal tissues, but their expression decreases in the neonatal period and reaches a comparatively low level in the adult animal. However, the capacity for AT 2 receptor re-expression is retained in the adult, because upregulation is a common response to circumstances of cardiovascular tissue damage, such as myocardial infarction, heart failure, and hypertension.
Activation of AT 2 receptors by the binding of Ang II stimulates a hormonal cascade consisting of bradykinin (BK), NO, and cGMP, leading to vasodilation that is counterregulatory to the vasoconstriction induced by Ang II via AT 1 receptors. 2 AT 2 receptor-induced vasodilation has been unequivocally demonstrated in both resistance and capacitance vessels. 3, 4 In capacitance vessels, Ang II binding to the AT 2 receptor activates the BK B 2 receptor, stimulating the phosphorylation of endothelial NO synthase at its serine 633 and serine 1177 residues by a protein kinase A-dependent mechanism, inducing NO generation. 4 In mesenteric, uterine, and coronary small resistance arteries, Ang II-induced vasodilation is mediated by the BK/NO/cGMP pathway and is not subject to desensitization, as is AT 1 receptor-mediated vasoconstriction. In whole-animal studies, in the presence of AT 1 receptor blockade, Ang II induces sustained vasodilation and hypotension that is abolished by AT 2 receptor antagonist PD-123319 and is mediated by the BK/NO/cGMP pathway. 5, 6 Thus, it is now generally accepted that the AT 2 receptor induces counterregulatory vasodilation that opposes AT 1 receptor-mediated vasoconstriction.
Because AT 2 receptor expression is developmentally regulated, and its activation has been described as inhibitory to flow-mediated dilation in hypertensive animals, Pinaud et al, 7 in this issue, hypothesized that AT 2 receptor function might behave differently in the resistance arteries of aged rats compared with nonaged control adult rats. As expected, their results show that resistance arteries from old rats had lower flow-and NO-mediated vasodilation and lower endothelial NO synthase expression than that of young control rats. However, a surprising finding was that, in old rats, AT 2 receptor blockade improved flow-mediated dilation, suggesting an unusual vasoconstrictor action mediated by the AT 2 receptor. Interestingly, the aging process was associated with increased AT 2 receptor expression, mainly in vascular smooth muscle cells rather than endothelial cells. Activation of the receptor induced direct vasoconstriction that was independent of the presence of the endothelium accompanied by increased reactive oxygen species. Both the increase in reactive oxygen species and the vasoconstriction were reversed by the antioxidant Tempol. In old rats, treatment with the vasodilator hydralazine also reduced AT 2 -receptor induction of reactive oxygen species and direct vasoconstriction, enhancing flowmediated vasodilation. This observation is consistent with earlier work showing that hydralazine is an antioxidant. Differences in AT 2 receptor expression and function between young and aged rats, as demonstrated in this and other studies, are summarized in the Table. The findings described in this article raise a number of important questions, the answers to which await future investigation. First, because this is the first description, is the vasoconstrictor action mediated by AT 2 receptors in old rats a replicable finding? Second, because AT 2 receptors clearly induce vasodilation in younger animals, what is the molecular switch that converts agonist activation of AT 2 receptors from vasodilator to vasoconstrictor during the aging process? Is this related simply to changes in cellular expression (vascular smooth muscle versus endothelium)? In particular, as rats age, does the BK/NO/cGMP vasodilator cascade become less sensitive or responsive to AT 2 receptor activation? Alternatively, is there a cell signaling switch that converts AT 2 receptor inhibition of mitogen-activated protein kinase (extracellular signal-related kinase 1/2) phosphorylation into stimulation? Third, at what juncture in vascular maturation does the transformation of AT 2 receptors from vasodilator to vasoconstrictor occur? Fourth, by what mechanism does hydralazine correct AT 2 receptor-mediated vasoconstriction and accumulation of reactive oxygen species, restoring flowmediated dilation? Is this simply related to hydralazine's previously described direct antioxidant action? Fifth, are the results of this study in rats applicable to humans? A vanishingly small number of studies indeed are available on the expression and function of AT 2 receptors in humans. The only available study on microvascular AT 2 receptor expression and action in humans demonstrates that the receptor can be induced chronically in hypertensive diabetic subjects by AT 1 receptor blockade and, under these circumstances, mediates vasodilation. 8 AT 1 receptor blockade increases vascular AT 2 receptor expression and interrupts Ang II negative feedback on renin secretion stimulating the production of Ang II, which is available to act at unblocked AT 2 receptors. If the upregulated AT 2 receptors induce direct vasoconstriction in aging humans, as described for the rat in this article, AT 1 receptor blockers would be potentially dangerous drugs in the elderly. However, AT 1 receptor blockers in elderly humans are clearly efficacious in controlling blood pressure, preventing stroke, and reducing vascular elasticity. 9 There is no suggestion of a vasoconstrictor action of AT 1 receptor blockade in elderly hypertensive subjects, with large numbers of elderly patients included in the many clinical trials reported to date. Therefore, the findings reported in this article in the rat are not necessarily applicable to humans. 
